Full history for every metric is available with a Kvantra account
Icosavax, Inc. (ICVX)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 2 | 8 | 1 |
| Operating profit | $m | -95 | |||||
| Net profit | $m | - | - | -5 | -19 | -68 | -88 |
| EPS reported | $ | -2.23 | |||||
| Operating cashflow per share | $ | -1.55 | |||||
| Capex per share | $ | 0.28 | |||||
| FCF per share | $ | -1.83 | |||||
| Free cash flow | $m | -73 | |||||
| Net debt | $m | -210 | |||||
| Book value equity | $m | 218 | |||||
| Book value per share | $ | 5.49 | |||||
| Number of shares | m | 39.73 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 1.45 | |||||
| P/S LTM | x | 541.95 | |||||
| P/FCF LTM | x | -4.33 | |||||
| EV/EBITDA LTM | x | -2.82 | |||||
| EV/Sales LTM | x | 455.96 | |||||
| Earnings Yield LTM | % | -28.04% | |||||
| FCF Yield | % | -23.08% | |||||
| Quality | |||||||
| ROE | % | -40.55% | |||||
| ROIC | % | -40.37% | |||||
| Operating margin | % | -16333.0% | |||||
| Gross margin | % | -216.67% | |||||
| FCF/Sales | % | -12506.5% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -92.54% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -8.28 | |||||
| Net Debt/EBITDA | x | 0.53 | |||||
| EBIT/Net interest | x | 0.00 | |||||
| Net debt/market cap | % | -66.42% | |||||
| Net debt/Equity | x | -0.96 | |||||
| Gross debt/equity | x | 0.04 | |||||
Company overview
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Icosavax, Inc. (ICVX)
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free